Exploring the Impact of Antireflux Treatment on Risk of Esophageal Adenocarcinoma in Patients With Barrett’s Esophagus: Insights from a Mendelian Randomization Study

We would like to provide insights on the recent study by Åkerström et al.1 This multinational cohort study indicates that Barrett's esophagus patients undergoing antireflux surgery do not have a reduced risk of developing esophageal adenocarcinoma compared with those using antireflux medication.1 Barrett's esophagus, due to its higher risk of esophageal adenocarcinoma, is a focus for cancer prevention.2 Although some studies suggest that medical antireflux can slow the progression of Barrett's esophagus to esophageal adenocarcinoma, this effect remains controversial.